Instructional Course - Requires Course Pass, Additional Registration Required

Instructional Course

043IC - Novel Agents & Concepts in the Management of Hormone-Naïve & Castrate-Resistant Prostate Cancer (traducido en español)

Sunday, May 20
7:30 AM - 9:30 AM
Location: MCC WEST, 2002

This course will include short didactic lectures followed by case presentations to give attendees an understanding of the many new FDA-approved agents, as well as existing standard therapies, for advanced prostate cancer-both non-metastatic and metastatic CRPC. Particular attention will be devoted to sequencing the new agents and positioning them as compared to older existing therapies. The cost effectiveness of new and existing agents will also be addressed.

Learning Objectives:

Judd W. Moul

Duke University

Judd W Moul, MD, FACS is the James H Semans Professor of Surgery at Duke University. Dr Moul is a prostate cancer researcher, busy urologic clinician and surgeon at the Duke Cancer Institute. He has performed over 2000 radical retropubic prostatectomies and continues to do this surgery very actively. He is involved in clinical trials and outcomes research and has published extensively in the field for over 25 years. He is past receipient of the AUA Gold Cystoscope Award and is a retired Colonel in the US Army Medical Corps having served for 26 years before joining the Duke faculty in 2004. He served as division chief of urology at Duke from 2004 to 2011 and then transitioned to team lead for prostate cancer at the Duke Cancer Institute. He has been a visiting professor at many centers in the US and around the World and has been quoted in major press outlets related to prostate cancer over many years. He has been a grantee of the US Army, the NIH and many private organizations related to clinical and basic aspects of prostate cancer and disease. He has been an active contributor to the AUA for many years inclding course director for various prostate cancer programs and courses. He is on the Executive Committee for the American Joint Commission for Cancer (AJCC).

Presentation(s):

Send Email for Judd Moul

LAWRENCE I. Karsh

Attending Urologist and Director of Research

Lawrence I. Karsh, MD, FACS
Dr. Karsh completed his General Surgical training at The University of Colorado Health Sciences Center and his Urology residency at Brigham and Women’s Hospital/Harvard Medical School.
Dr. Karsh is a co-founder of The Urology Center of Colorado where he serves as an attending Urologist and Director of Research. He is a certified principal investigator with an experience of more than 226 clinical trials. Dr. Karsh has authored a number of peer-reviewed publications and serves on the editorial boards for “Urologists in Cancer Care” and “Bladder Cancer.”
He is an active member of the AUA, SUO, ASCO, SWOG, SBUR and the Denver Academy of Surgeons. He serves on the bladder cancer subcommittee and is on the advisory board for the SUO Clinical Trials Consortium and BCAN.

Presentation(s):

Send Email for LAWRENCE Karsh

Christopher Sweeney

Dana Farber Cancer Institute

A Medical Oncologist at the Dana-Farber Cancer Institute (MA, USA), Christopher J. Sweeney is a member of the American Society of Clinical Oncology, the Eastern Cooperative Oncology Group-ACRIN, Alliance and the American Association for Cancer Research. In 1992 Dr Sweeney received his medical degree from the University of Adelaide (Australia) and completed an internship at the Royal Adelaide Hospital (Australia). Dr. Sweeney did his residency in internal medicine at Gundersen Lutheran Medical Center (WI, USA) and a fellowship in hematology/oncology at Indiana University Medical Center (IN, USA), where he was later appointed Associate Director for Clinical Research for the Simon Cancer Center. Dr . Sweeney joined the Lank Center for Genitourinary Oncology at DFCI and Harvard Medical School (MA, USA) in 2009. His primary research interest is drug discovery and development. His academic focus is primarily on the management of genitourinary malignancies, with a focus on prostate and testicular cancer.

Presentation(s):

Send Email for Christopher Sweeney


Assets

043IC - Novel Agents & Concepts in the Management of Hormone-Naïve & Castrate-Resistant Prostate Cancer (traducido en español)

Slides

Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for Novel Agents & Concepts in the Management of Hormone-Naïve & Castrate-Resistant Prostate Cancer (traducido en español)